Biotech Investors Eye Early-Stage Venture Vacuum
This article was originally published in Start Up
Data compiled and analyzed by the Biotechnology Industry Organization and discussed at its recent CEO & Investor meeting in New York begs the question: why aren’t more new biotechs being started when investor and acquirer demand is so high?
You may also be interested in...
Since 2013, investors have rallied around biotech IPOs like never before. START-UP looks at the current window and the implications of investor enthusiasm for newly public companies.
Oncology companies have been garnering the most investment from venture capital firms over the last 10 years due to their high levels of innovation, according to a new report from the industry group.
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.